Copper is required for oncogenic BRAF signaling and tumorigenesis
暂无分享,去创建一个
Michelle L. Turski | Donita C. Brady | Matt Crowe | Sharon L. Campbell | Christopher M. Counter | Apirat Chaikuad | Stefan Knapp | G. Hobbs | Xiaojie Yao | Kunhong Xiao | Dennis J. Thiele
[1] Kate Owen,et al. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2016, eLife.
[2] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[3] S. Howell,et al. Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. , 2012, Biochemical pharmacology.
[4] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[5] B. Ancrile,et al. Targeting eNOS in pancreatic cancer. , 2012, Cancer research.
[6] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[7] D. Thiele,et al. A Novel Role for Copper in Ras/Mitogen-Activated Protein Kinase Signaling , 2012, Molecular and Cellular Biology.
[8] Kunhong Xiao,et al. Multiple ligand-specific conformations of the β2-adrenergic receptor. , 2011, Nature chemical biology.
[9] Ryan T. Strachan,et al. Distinct Phosphorylation Sites on the β2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of β-Arrestin , 2011, Science Signaling.
[10] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Rosen,et al. Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.
[12] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[13] Sin-Ho Jung,et al. Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy , 2010, Molecular Cancer Therapeutics.
[14] P. Zipfel,et al. Ral activation promotes melanomagenesis , 2010, Oncogene.
[15] C. Counter,et al. ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. , 2009, Carcinogenesis.
[16] A. Krasnitz,et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. , 2009, Cancer cell.
[17] Paul Reichert,et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. , 2009, Biochemistry.
[18] D. Thiele,et al. New Roles for Copper Metabolism in Cell Proliferation, Signaling, and Disease* , 2009, Journal of Biological Chemistry.
[19] N. Ahn,et al. Isolation of Intrinsically Active (MEK-independent) Variants of the ERK Family of Mitogen-activated Protein (MAP) Kinases*♦ , 2008, Journal of Biological Chemistry.
[20] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[21] Eric S. Lander,et al. Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.
[22] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[23] M. Serrano,et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.
[24] K. Ashkan,et al. Wilson's disease , 2007, The Lancet.
[25] R. Vachet,et al. Using metal-catalyzed oxidation reactions and mass spectrometry to identify amino acid residues within 10 Å of the metal in Cu-binding proteins , 2006, Journal of the American Society for Mass Spectrometry.
[26] D. Thiele,et al. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. , 2006, Cell metabolism.
[27] Brendan K Faherty,et al. Optimization and Use of Peptide Mass Measurement Accuracy in Shotgun Proteomics*S , 2006, Molecular & Cellular Proteomics.
[28] K. Hahn,et al. PB1 Domain-Dependent Signaling Complex Is Required for Extracellular Signal-Regulated Kinase 5 Activation , 2006, Molecular and Cellular Biology.
[29] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[30] N. C. Price,et al. How to study proteins by circular dichroism. , 2005, Biochimica et biophysica acta.
[31] R. Vachet,et al. Metal-catalyzed oxidation reactions and mass spectrometry: the roles of ascorbate and different oxidizing agents in determining Cu-protein-binding sites. , 2005, Analytical biochemistry.
[32] P. Khavari,et al. Mek1 Alters Epidermal Growth and Differentiation , 2004, Cancer Research.
[33] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[34] M. L’Abbé,et al. Copper Modulates the Degradation of Copper Chaperone for Cu,Zn Superoxide Dismutase by the 26 S Proteosome* , 2003, Journal of Biological Chemistry.
[35] M. Mann,et al. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.
[36] D. Thiele,et al. Characterization of Mouse Embryonic Cells Deficient in the Ctr1 High Affinity Copper Transporter , 2002, The Journal of Biological Chemistry.
[37] C. Der,et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. , 2002, Genes & development.
[38] D. Thiele,et al. Biochemical and Genetic Analyses of Yeast and Human High Affinity Copper Transporters Suggest a Conserved Mechanism for Copper Uptake* , 2002, The Journal of Biological Chemistry.
[39] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[40] M. White,et al. Contribution of the ERK5/MEK5 Pathway to Ras/Raf Signaling and Growth Control* , 1999, The Journal of Biological Chemistry.
[41] C. Der,et al. The Mitogen-activated Protein Kinase Phosphatases PAC1, MKP-1, and MKP-2 Have Unique Substrate Specificities and Reduced Activity in Vivo toward the ERK2 sevenmaker Mutation (*) , 1996, The Journal of Biological Chemistry.
[42] D. Kessler,et al. Biochemical and biological analysis of Mek1 phosphorylation site mutants. , 1995, Molecular biology of the cell.
[43] H. Nazer,et al. Wilson's Disease. , 1991, Annals of Saudi medicine.
[44] C. Counter,et al. A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. , 2006, Methods in enzymology.